1 Department of Medicine, Oncology Unit, Patras University Hospital, Rio-Patras; 2 Department of Medicine, Second Division of Medical Oncology, Metaxa Cancer Hospital, Athens, Greece.
*E-mail: ckosm@ath.forthnet.gr
A 69-year-old woman presented in October 1998 with abdominal pain and distension. On physical examination, ascites and tenderness on palpating the lower abdominal area were found. An abdominal computed tomography (CT) scan revealed a 4.5 cm mass in the left ovary with multiple peritoneal implants and ascites. The serum tumor marker CA 125 was 190 U/ml (normal, <32), whereas thyroid hormones were within normal limits: thyroid-stimulating hormone (TSH) 5.1 U/ml, thyroxine 7.2 U/ml, tri-iodothyronine 1.2 U/ml.
She underwent a staging laparotomy and abdominal hysterectomy with bilateral salpingo-ophorectomy and omentectomy stage IIIC disease was detected. Histology was consistent with serous cystadenocarcinoma grade 12. She received six cycles of chemotherapy with paclitaxel and carboplatin or cisplatin (alternate cycles). Toxicity was limited to grade 1 peripheral neuropathy with mild numbness in a glove-and-stocking distribution. No alopecia was evident at this point. At the end of chemotherapy, an abdominal CT scan showed complete radiological remission and serum CA 125 within normal limits.
One month later, she developed clinical signs of hypothyroidism, and TSH was 90 U/ml. On questioning, it appeared that the patient elected on her own to discontinue thyroxine replacement at the start of chemotherapy without informing the medical team. Thyroxine replacement therapy was recommenced and 2 months later thyroid hormones were within normal limits. As soon as thyroid function was restored, alopecia grade 2 appeared, 3 months after the completion of chemotherapy. Grade 2 alopecia was present for almost 2 months, after which hair regrowth was apparent.
Nine months later, the patient developed intra-abdominal relapse, and despite salvage treatment attempts, she died 3 months later from progressive disease.
The current case represents a very rare, probably unique, clinical entity. A possible explanation of the delayed onset of alopecia after the completion of paclitaxel chemotherapy could be attributed to the combined effects of thyroid hormones and chemotherapy upon the biological cycle of hair. Each hair follicle continually goes through three stages: anagen (growth), catagen (involution), and telogen (rest) [1]. Anagen is followed by catagen when hair follicles go through a highly controlled process of involution. Ultimately, the hair follicle enters the telogen stage when the hair shaft matures into a club hair which is eventually shed from the follicle [1]. The telogen stage lasts 23 months before the follicles re-enter the anagen stage and the cycle is repeated. At any given point, most of the hair follicles can be found in the anagen phase with only a small percentage in the telogen phase and just a few in the catagen phase (Figure 1).
|
In our clinical case, the patient was hypothyroid during chemotherapy with paclitaxel, due to the cessation of thyroxine replacement. As a result, most hair follicles probably entered the telogen stage (Figure 1). We hypothesize that paclitaxel could not act in the hair follicles that were in the telogen stage and thus no alopecia appeared (Figure 1). Once thyroid function was restored, it is likely that the telogen stage was completed leading to telogen effluvium, and alopecia grade 2 developed. Another factor that may contribute to the development of alopecia is the possibility of paclitaxel accumulating in the scalp and causing anagen effluvium. Since an increase in the percentage of follicles in the telogen stage leads to excessive shedding and telogen effluvium, drugs that reduce the percentage of hair follicles in this stage or prevent the evolution of hair follicles to this stage could be valuable in treating hair loss [3, 5].
In conclusion, the above clinical case represents a very rare clinical phenomena that shows an interesting interaction of two different factors in the regulation of hair growth. The mechanism of action and interaction of various factors such as thyroid hormones and chemotherapeutic agents in the biological cycle of hair growth is still poorly understood. Progress in our understanding of the biology and pathophysiology of hair follicles should lead to more effective therapies for disorders of hair growth, including chemotherapy-induced alopecia.
S. Sofroniadou1, C. Kosmas2*, T. Kourelis1, T. Makatsoris1, A. Koutras1, A. Onienadoum1 & H. P. Kalofonos1
1Department of Medicine, Oncology Unit, Patras University Hospital, Rio-Patras; 2Department of Medicine, Second Division of Medical Oncology, Metaxa Cancer Hospital, Athens, Greece. (*E-mail: ckosm@ath.forthnet.gr)
References
1. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999; 341: 491497.
2. Paus R. Control of the hair cycle and hair diseases as cycling disorders. Curr Opin Dermatol 1996; 3: 248258.
3. Lindner G, Botchkareva VA, Botchkareva NV et al. Analysis of apoptosis during hair follicle regression. Am J Pathol 1997; 151: 16011617.[Abstract]
4. Cancer, cancer therapy and hair. Lancet 1983; 2: 11771178.[CrossRef][ISI][Medline]
5. Cline BW. Prevention of chemotherapy-induced alopecia: a review of the literature. Cancer Nurs 1984; 7: 221228.[Medline]